Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT04656210
Active, not recruiting Observational

Myotonic Dystrophy - Vascular and Cognition

NCT04656210 · tracked via the Priya Life Science France tracker
Phase
Observational
Started
2021-10-14
Last updated
2026-05-22

Condition(s) studied

Myotonic Dystrophy 1DiabetesCarbohydrate Intolerance

Investigational drug(s) / intervention(s)

MRIneuropsychological tests

MRI: Non conventional MRI (35 minutes)

neuropsychological tests: Standardized and quantified neuropsychological assessment

Study summary

The cognitive disorders of adult forms of myotonic dystrophies type 1 are heterogeneous (impairment of executive functions, visio construction and theory of the mind, which can progress to the stage of dementia). Nevertheless, patients have very different degrees of cognitive impairment. Expansion of CTG triplets disrupts the alternative splicing of mRNAs of various proteins, including the insulin receptor and Tau protein. Type 2 diabetes, associated with peripheral insulin resistance, is therefore common in this pathology.

Type 2 diabetes,could to explain the cognitive impairment of patients, through the accelerated development of brain lesions (especially tauopathy and cerebral atrophy).

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: * Molecularly proven type 1 myotonic dystrophy * Voluntary, having given informed consent * Socially insured patient * Patient willing to comply with all study procedures and duration (3 hours + MRI 35 minutes) * Patient insured under the French social security system * Signed consent form Exclusion Criteria: * Neurological history other than neuropathy: epilepsy, stroke, dementia * Pregnancy or breastfeeding or woman of childbearing age without effective contraception (a pregnancy test will be done) * Contra indication to MRI * Person under guardianship or curators * Persons of full age deprived of their liberties by a judicial or administrative decision * Major comorbidity considered as a contraindication by the investigator (cancer, unstable angina, etc.).

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Hopital Roger Salengro, CHU Lille Lille France

More University Hospital, Lille trials in France

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04656210 on ClinicalTrials.gov ↗ ← All trials in France